BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive
clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic
lymphoid organs called tertiary lymphoid structures (TLS),. Although TLS have been found to …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced
soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary …

Only a minority of patients derive long-term clinical benefit from anti-programmed cell death
protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal …

The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …